An analog of desoxycorticosterone which is substituted by a hydroxyl group at the C-18 position.
The practice of caring for individuals in the community, rather than in an institutional environment with resultant effects on the individual, the individual's family, the community, and the health care system.
The process by which a person or group of persons comes to be regarded or treated as lacking in human qualities.
Insects of the family Formicidae, very common and widespread, probably the most successful of all the insect groups. All ants are social insects, and most colonies contain three castes, queens, males, and workers. Their habits are often very elaborate and a great many studies have been made of ant behavior. Ants produce a number of secretions that function in offense, defense, and communication. (From Borror, et al., An Introduction to the Study of Insects, 4th ed, p676)
Special hospitals which provide care to the mentally ill patient.
People who frequently change their place of residence.
People who leave their place of residence in one country and settle in a different country.
A group of telomere associated proteins that interact with TRF1 PROTEIN, contain ANKYRIN REPEATS and have poly(ADP-ribose) polymerase activity.

Aldosterone and renin in essential hypertension. (1/17)

A review of some recent laboratory findings indicates definite disturbances in aldosterone metabolism and regulation in patients with mild essential hypertension: (a) a significant mean increase in plasma aldosterone concentration in patients with mild and stable essential hypertension, in contrast to the absence of any difference in patients with labile borderline essential hypertension when in a normotensive phase, compared with control subjects; and (b) a significant mean decrease in metabolic clearance rate of aldosterone, associated with a 12% decrease in hepatic blood flow and an increased binding of aldosterone to a transcortin-like plasma globulin. The secretion rate of 18-hydroxy-11-deoxycorticosterone is above the upper range of normal in 60% of patients with mild, uncomplicated essential hypertension. The incidence of low-renin hypertension, when age and race are taken into account, is much lower than previously assumed. Unless measurements are repeated over a long period, one or two low values of plasma renin cannot be considered a permanent marker indicating a special category of patients with essential hypertension. Tonin, a new enzyme discovered by Boucher, which forms angiotensin II directly from a plasma protein, from the tetradecapeptide substrate and from angiotensin I, is present in most tissues, but in highest concentration in the submaxillary gland. This enzyme is under the control of beta-adrenergic receptors.  (+info)

Preclinical Cushing's syndrome due to ACTH-independent bilateral macronodular adrenocortical hyperplasia with excessive secretion of 18-hydroxydeoxycorticosterone and corticosterone. (2/17)

A 64-year-old woman developed hypertension and hypokalemia, due to ACTH-independent bilateral macronodular adrenocortical hyperplasia (AIMAH) with excessive secretion of 18-hydroxydeoxycorticosterone and corticosterone. Plasma cortisol did not show a diurnal rhythm, and was not suppressed by dexamethasone (8 mg). Plasma cortisol responded to ACTH and was increased by hypoglycemia without modifying ACTH levels. Radiological studies demonstrated that adrenal glands were enlarged with macronodules. Although the patient exhibited a low plasma renin activity and aldosterone levels, hypokalemia and hypertension were observed. Hormonal findings would support the hypothesis that the tumor of AIMAH originated from cells of the upper zona fasciculata.  (+info)

Effect of uni-adrenalectomy on blood pressure in a patient with excessive adrenal 18-hydroxy-11-deoxycorticosterone production bilaterally. (3/17)

A 46-year-old woman was presented with mineralocorticoid excess syndrome and a large mass originating from the right adrenal gland. Clinical examination before right adrenalectomy revealed elevated serum concentrations of 18-hydroxy-11-deoxycorticosterone (18-OH-DOC) both systemically and in the adrenal veins bilaterally. Histopathological and immunohistochemical analyses of the surgical specimen demonstrated adrenal hyperplasia of outer fasciculata cells, and the presence of cystic mass. The adrenalectomy ameliorated her blood pressure (BP) from 156/96 mmHg to 148/87 mmHg with a concomitant increase of serum potassium concentration from 3.1 mEq/l to 3.5 mEq/l. These results suggest that uni-adrenalectomy is, at least in part, effective in ameliorating not only BP but also potassium concentration in a patient of adrenal hyperplasia with excessive bilateral 18-OH-DOC production.  (+info)

Effect of aminoglutethimide on blood pressure and steroid secretion in patients with low renin essential hypertension. (4/17)

An inhibitor of adrenal steroid biosynthesis, aminoglutethimide, was administered to seven patients with low renin essential hypertension, and the antihypertensive action of the drug was compared with its effects on adrenal steroid production. In all patients aldosterone concentrations in plasma and urine were within normal limits before the study. Mean arterial pressure was reduced from a pretreatment value of 117+/-2 (mean+/-SE) mm Hg to 108+/-3 mm Hg after 4 days of aminoglutethimide therapy and further to 99+/-3 mm Hg when drug administration was stopped (usually 21 days). Body weight was also reduced from 81.6+/-7.2 kg in the control period to 80.6+/-7.0 kg after 4 days of drug treatment and to 80.1+/-6.7 kg at the termination of therapy. Plasma renin activity was not significantly increased after 4 days of treatment but had risen to the normal range by the termination of aminoglutethimide therapy. Mean plasma concentrations of deoxycorticosterone and cortisol were unchanged during aminoglutethimide treatment whereas those of 18-hydroxydeoxycorticosterone, progesterone, 17alpha-hydroxyprogesterone, and 11-deoxycortisol were increased as compared to pretreatment values. In contrast, aminoglutethimide treatment reduced mean plasma aldosterone concentrations to about 30% of control values. Excretion rates of 16beta-hydroxydehydroepiandrosterone, 16-oxo-androstenediol, 17-hydroxycorticosteroids and 17-ketosteroids, and the secretion rate of 16beta-hydroxydehydroepiandrosterone were not significantly altered by aminoglutethimide treatment whereas the excretion rate of aldosterone was reduced from 3.62+/-0.5 (mean+/-SE) in the control period to 0.9+/-0.2 mug/24 h after 4 days and to 1.1+/-0.3 mug/24 h at the termination of aminoglutethimide treatment. The gradual lowering of blood pressure and body weight during aminoglutethimide therapy is consistent with the view that the antihypertensive effect of the drug is mediated through a reduction in the patients' extracellular fluid volume, probably secondary to the persistent decrease in aldosterone production. The observation that chronic administration of aminoglutethimide lowered blood pressure in these patients and elevated their plasma renin activity to the normal range without decreasing production of the adrenal steroids, deoxycorticosterone, 18-hydroxydeoxycorticosterone, and 16beta-hydroxydehydroepiandrosterone, makes it unlikely that these steroids are responsible either for the decreased renin or the elevated blood pressure in patients with low renin essential hypertension.  (+info)

The regulation of plasma 18-hydroxy 11-deoxycorticosterone in man. (5/17)

18-hydroxy 11-deoxycorticosterone (18-OH DOC), a weak mineralocorticoid, was estimated by a radioimmunoassay procedure after purification in 49 patients with hypertension and 38 normal control subjects. The sensitivity of the method was 2-4 pg; there was no detectable blank, and the precision was 9-10%. In normal subjects the absolute plasma levels were similar to those of aldosterone. ACTH administration produced a 23-fold increase, and sodium restriction resulted in a 4-fold increase (5.4+/-0.7-20.5+/-3.0 ng/dl). On the other hand, the plasma levels of 18-OH DOC declined by nearly 50% with upright posture or angiotensin II infusion. During both of these procedures, plasma aldosterone levels significantly increased. Patients with normal and low renin hypertension had similar changes in plasma 18-OH DOC levels with sodium restriction. However, the mean high sodium level in the normal renin essential hypertension group (11.6+/-1.6 ng/dl) was significantly greater (P is less than 0.001) than in the control group (5.4+/-0.7 ng/dl). In addition, at least 22% and perhaps as high as 37% of the hypertensive subjects had levels greater than the upper limits of normal on a high sodium intake. Differences between the groups were less impressive in the sodium-restricted studies. There were no significant differences in age, duration of hypertension, sodium balance, serum sodium, potassium, or blood urea nitrogen in those patients who had elevated levels of plasma 18-OH DOC. Patients with primary aldosteronism had levels within the normal range on both dietary intake. However, in contrast to the other groups there were no significant changes in the plasma levels with sodium restriction. Thus, a significant number of patients with essential hypertension presumably have an alteration in 18-OH DOC secretion.  (+info)

Plasma levels of 18-hydroxy-11-deoxycorticosterone in essential hypertension. (6/17)

In order to investigate the role of 18-hydroxy-11-deoxycorticosterone (18-OH-DOC) in essential hypertension (EH), the responses of plasma 17-OH-DOC to 7 stimulation tests (furosemide test, adrenal suppression test, angiotensin II infusion test, adrenal stimulation test, metopirone test, saline infusion test and potassium chloride infusion test) and the circadian rhythm were investigated in 18 patients with essential hypertension (low renin group: 8, and normal renin group: 10). From the present study, it micht be thought that plasma 18-OH-DOC does not play an important role in the suppression of PRA in patients with low PRA.  (+info)

Trend analysis of serum progesterone, deoxycorticosterone, deoxycorticosterone sulfate, cortisol, corticosterone, 18-hydroxydeoxycorticosterone and estradiol in early neonates. (7/17)

To elucidate the origin and regulatory mechanism of deoxycorticosterone (DOC) and deoxycorticosterone sulfate during fetal life, the levels of serum DOC, DOC sulfate, progesterone, cortisol, corticosterone and 18-hydroxydeoxycorticosterone (18OH-DOC) were determined in the fraction separated on high performance liquid chromatogram (HPLC) by radioimmunoassay (RIA) using the serum from normal newborn. Elimination curves both of serum DOC and DOC sulfate showed two phases: rapidly decreasing and slowly decreasing ones. Both serum DOC and DOC sulfate correlated with progesterone (r = 0.340, p less than 0.01; r = 0.737, p less than 0.01, respectively). They also correlated with cortisol (DOC, r = 0.467, p less than 0.01; DOC sulfate, r = 0.549, p less than 0.01, respectively). Serum DOC reached normal adult levels by 16 hrs after birth. However serum DOC sulfate concentration was maintained high throughout the entire early neonatal period. On the contrary, the changes in serum cortisol, corticosterone and 18OH-DOC showed a peak surge in the initial phase after delivery. Both serum corticosterone and 18OH-DOC correlated with cortisol (r = 0.518, p less than 0.01; r = 0.410, p less than 0.01, respectively). These findings suggest that, in the fetus, serum DOC and DOC sulfate are mainly produced at extraadrenal sites isolated from normal mineralocorticoids synthesis and after birth they begin to be formed at adrenal glands.  (+info)

Suppression of adrenal renin in Dahl salt-sensitive rats. (8/17)

We previously showed that adrenal renin is highest in the rat zona glomerulosa (ZG) and that low sodium or high potassium and nephrectomy increase adrenal ZG renin and aldosterone. Dahl salt-sensitive rats (S) have been shown to have lower plasma renin activity and plasma aldosterone and higher plasma 18-hydroxy-11-deoxycorticosterone than Dahl salt-resistant rats (R). In this study we assess the possible role of adrenal ZG renin in the suppression of aldosterone in S rats. Adrenal ZG renin was significantly decreased in S as compared with R rats even at 6 weeks of age, when both S and R rats are still normotensive (S = 7.2 +/- 0.2, R = 18.0 +/- 1.6 ng angiotensin I/mg protein/hr). Adrenal ZG aldosterone was also significantly lower in S than in R rats (S = 21.1 +/- 4.3, R = 39.5 +/- 3.6 ng/mg protein). Furthermore, the rise in adrenal ZG renin and aldosterone after nephrectomy in S rats was significantly less than that in R rats. To determine if the suppressed adrenal ZG renin of S rats is due to volume expansion, we studied the effect of a sodium-deficient diet on adrenal ZG renin in S and R rats. After 2 weeks of a sodium-deficient diet S rats had significantly lower basal adrenal ZG renin than did R rats (S = 7.6 +/- 0.4, R = 21.7 +/- 1.9 ng angiotensin I/mg protein/hr) and a marked blunting of the adrenal ZG renin response to nephrectomy (S = 13.6 +/- 1.1, DR = 167 +/- 16.1 ng angiotensin I/mg protein/hr).(ABSTRACT TRUNCATED AT 250 WORDS)  (+info)

18-Hydroxydesoxycorticosterone is a steroid hormone that is produced by the adrenal gland. It is an intermediate in the biosynthesis of aldosterone, which is the major hormone responsible for regulating sodium and potassium balance in the body. 18-Hydroxydesoxycorticosterone itself has minimal biological activity, but it is converted to aldosterone by the enzyme aldosterone synthase.

The medical relevance of 18-Hydroxydesoxycorticosterone lies in its role as a precursor to aldosterone and its potential use as a marker for certain adrenal gland disorders. For example, increased production of 18-Hydroxydesoxycorticosterone has been observed in some cases of primary hyperaldosteronism, which is a condition characterized by excessive aldosterone production leading to high blood pressure and low potassium levels. Measuring the levels of this hormone can help diagnose and manage such conditions.

Deinstitutionalization is a social policy aimed at transitioning individuals with mental illness or developmental disabilities out of long-term institutional care and reintegrating them into community-based settings. This process typically involves the closure of large institutions, such as psychiatric hospitals and state-run developmental centers, and the development of community-based services, such as group homes, supported housing, and case management.

The goal of deinstitutionalization is to provide individuals with disabilities more autonomy, dignity, and quality of life while also promoting their inclusion in society. However, it has been a controversial policy, with some critics arguing that insufficient community-based services have led to homelessness, incarceration, and other negative outcomes for some individuals who were deinstitutionalized.

Deinstitutionalization became a significant social movement in many developed countries during the mid-to-late 20th century, driven by changing attitudes towards disability, human rights advocacy, and evidence of the harmful effects of institutionalization. However, its implementation has varied widely across different regions and populations, with varying degrees of success.

Dehumanization is a process or phenomenon in which a person or group is treated or regarded as lacking basic human qualities and emotions, such as compassion, empathy, or individuality. This can occur through various means, including language, propaganda, social policies, or actions that deprive individuals of their rights, dignity, or freedom. Dehumanization can have serious consequences, including increased prejudice, discrimination, and violence against the targeted group. It is considered a violation of basic human rights and is often associated with totalitarian regimes, genocide, and other large-scale human rights abuses.

I believe you may have accidentally omitted the word "in" from your search. Based on that, I'm assuming you are looking for a medical definition related to the term "ants." However, ants are not typically associated with medical terminology. If you meant to ask about a specific condition or concept, please provide more context so I can give a more accurate response.

If you are indeed asking about ants in the insect sense, they belong to the family Formicidae and order Hymenoptera. Some species of ants may pose public health concerns due to their ability to contaminate food sources or cause structural damage. However, ants do not have a direct medical definition associated with human health.

A psychiatric hospital is a type of medical facility that specializes in the treatment and care of patients with mental illnesses or disorders. These hospitals provide inpatient and outpatient services, including evaluation, diagnosis, and therapy for various psychiatric conditions such as depression, bipolar disorder, schizophrenia, anxiety disorders, personality disorders, and substance use disorders.

Psychiatric hospitals typically have a multidisciplinary team of healthcare professionals, including psychiatrists, psychologists, social workers, nurses, and occupational therapists, who work together to provide comprehensive care for patients. The treatment modalities used in psychiatric hospitals may include medication management, individual and group therapy, psychoeducation, and milieu therapy.

Psychiatric hospitals may also offer specialized programs for specific populations, such as children and adolescents, older adults, or individuals with co-occurring mental illness and substance use disorders. The goal of psychiatric hospitals is to stabilize patients' symptoms, improve their functioning, and help them develop the skills necessary to manage their mental health condition in the community.

In the context of medical terminology, "transients" and "migrants" are often used to describe populations that are moving or have recently moved from one place to another. These terms can refer to individuals who are temporarily residing in a location for work, school, or other reasons (transients), as well as those who are planning to settle permanently in a new location (migrants).

A "transient" population may include people who are traveling for leisure, working on temporary contracts, attending school in a different city or country, or serving in the military. These individuals typically have a specific destination and time frame for their stay, and they may not have established long-term social or medical support systems in the area.

A "migrant" population, on the other hand, refers to people who are moving with the intention of settling permanently in a new location. This can include individuals and families who are seeking better economic opportunities, fleeing political unrest or natural disasters, or reuniting with family members in another country. Migrants often face unique challenges when it comes to accessing healthcare services, as they may not have established relationships with healthcare providers in their new location, may face language barriers, and may lack familiarity with the local healthcare system.

It's important to note that these terms are not mutually exclusive, and an individual or group could be considered both transient and migrant depending on the context. For example, a refugee family who is resettling permanently in a new country might initially be considered transients as they establish themselves in their new home, but over time they would become part of the migrant population.

An emigrant is a person who leaves their native country to live permanently in another country. The process of leaving one's country to settle in another is called emigration.

On the other hand, an immigrant is a person who comes to live permanently in a foreign country. The process of coming to live permanently in a new country is called immigration.

So, the main difference between emigrants and immigrants lies in the perspective: emigrants are people leaving their own country, while immigrants are people entering a new country.

Tankyrases are a group of proteins that belong to the poly (ADP-ribose) polymerase (PARP) family, specifically PARP5a and PARP5b. They play roles in various cellular processes such as telomere maintenance, Wnt signaling pathway regulation, and protein trafficking. Tankyrases add poly(ADP-ribose) chains to their target proteins, leading to changes in their function, localization, or stability. Dysregulation of tankyrases has been implicated in several diseases, including cancer.

18-hydroxydesoxycorticosterone MeSH D06.472.040.585.745 - pregnenolone MeSH D06.472.040.585.745.500 - 17-alpha- ... 18-hydroxycorticosterone MeSH D06.472.040.585.353.825 - tetrahydrocortisol MeSH D06.472.040.585.478 - 17-hydroxycorticosteroids ...
18-hydroxycorticosterone MeSH D04.808.745.745.654.252 - cortodoxone MeSH D04.808.745.745.654.339 - desoxycorticosterone MeSH ... 18-hydroxydesoxycorticosterone MeSH D04.808.745.745.654.473 - flurandrenolone MeSH D04.808.745.745.654.485 - flurogestone ...
18-hydroxydesoxycorticosterone MeSH D06.472.040.585.745 - pregnenolone MeSH D06.472.040.585.745.500 - 17-alpha- ... 18-hydroxycorticosterone MeSH D06.472.040.585.353.825 - tetrahydrocortisol MeSH D06.472.040.585.478 - 17-hydroxycorticosteroids ...
B1.650.940.800.575.100.18 Agave B1.650.940.800.575.100.18.249 B1.650.940.800.575.100.99.60.32 Agglutination G2.111.87.26 G2.111 ... 18-Hydroxydesoxycorticosterone D4.808.745.745.654.339.400 D4.210.500.745.745.654.339.400 19-Iodocholesterol D4.808.247.222. ... 18-Hydroxycorticosterone D4.808.745.745.654.237.400 D4.210.500.745.745.654.237.400 ...
B1.650.940.800.575.100.18 Agave B1.650.940.800.575.100.18.249 B1.650.940.800.575.100.99.60.32 Agglutination G2.111.87.26 G2.111 ... 18-Hydroxydesoxycorticosterone D4.808.745.745.654.339.400 D4.210.500.745.745.654.339.400 19-Iodocholesterol D4.808.247.222. ... 18-Hydroxycorticosterone D4.808.745.745.654.237.400 D4.210.500.745.745.654.237.400 ...
B1.650.940.800.575.100.18 Agave B1.650.940.800.575.100.18.249 B1.650.940.800.575.100.99.60.32 Agglutination G2.111.87.26 G2.111 ... 18-Hydroxydesoxycorticosterone D4.808.745.745.654.339.400 D4.210.500.745.745.654.339.400 19-Iodocholesterol D4.808.247.222. ... 18-Hydroxycorticosterone D4.808.745.745.654.237.400 D4.210.500.745.745.654.237.400 ...
B1.650.940.800.575.100.18 Agave B1.650.940.800.575.100.18.249 B1.650.940.800.575.100.99.60.32 Agglutination G2.111.87.26 G2.111 ... 18-Hydroxydesoxycorticosterone D4.808.745.745.654.339.400 D4.210.500.745.745.654.339.400 19-Iodocholesterol D4.808.247.222. ... 18-Hydroxycorticosterone D4.808.745.745.654.237.400 D4.210.500.745.745.654.237.400 ...
B1.650.940.800.575.100.18 Agave B1.650.940.800.575.100.18.249 B1.650.940.800.575.100.99.60.32 Agglutination G2.111.87.26 G2.111 ... 18-Hydroxydesoxycorticosterone D4.808.745.745.654.339.400 D4.210.500.745.745.654.339.400 19-Iodocholesterol D4.808.247.222. ... 18-Hydroxycorticosterone D4.808.745.745.654.237.400 D4.210.500.745.745.654.237.400 ...
... hydroxydesoxycorticosterone (27) phrases: heisenberg uncertainty principles & heisenbergs uncertainty principle (31-t) phrases ... hydroxydesoxycorticosterone (27) phrases: transmission electron microscopes & transmission electron microscopies (31) ... a. 3,4,5 - letters [20-195] b. tetragram [17-125,147,176,18-23,40,155,21,28] Pronunciation. Syllables. Entire Word. longest. a ... all 120 possible orders [2-208,3-18,8-20,9-92,10-84,12-92,122,152,18-154,20-156,213]. Consonants. Entire Word. all consonants, ...
doi: 10.1007/s10815-022-02538-5. Epub 2022 Jul 18. J Assist Reprod Genet. 2022. PMID: 35849255 ...
B1.650.940.800.575.100.18 Agave B1.650.940.800.575.100.18.249 B1.650.940.800.575.100.99.60.32 Agglutination G2.111.87.26 G2.111 ... 18-Hydroxydesoxycorticosterone D4.808.745.745.654.339.400 D4.210.500.745.745.654.339.400 19-Iodocholesterol D4.808.247.222. ... 18-Hydroxycorticosterone D4.808.745.745.654.237.400 D4.210.500.745.745.654.237.400 ...
18-Hydroxydesoxycorticosterone Preferred Term Term UI T043962. Date01/01/1999. LexicalTag NON. ThesaurusID NLM (1975). ... 18-Hydroxy-11-Desoxycorticosterone Term UI T043960. Date08/30/1982. LexicalTag NON. ThesaurusID UNK (19XX). ... 18-Hydroxy-11-Deoxycorticosterone Term UI T547848. Date08/08/2003. LexicalTag NON. ThesaurusID NLM (2005). ... 18 Hydroxydesoxycorticosterone Term UI T043961. Date01/13/1978. LexicalTag NON. ThesaurusID UNK (19XX). ...
18-Hydroxydesoxycorticosterone Preferred Term Term UI T043962. Date01/01/1999. LexicalTag NON. ThesaurusID NLM (1975). ... 18-Hydroxy-11-Desoxycorticosterone Term UI T043960. Date08/30/1982. LexicalTag NON. ThesaurusID UNK (19XX). ... 18-Hydroxy-11-Deoxycorticosterone Term UI T547848. Date08/08/2003. LexicalTag NON. ThesaurusID NLM (2005). ... 18 Hydroxydesoxycorticosterone Term UI T043961. Date01/13/1978. LexicalTag NON. ThesaurusID UNK (19XX). ...
X N0000168666 Collagen Type XI N0000168675 Collagen Type XII N0000168679 Collagen Type XIII N0000168672 Collagen Type XVIII ... Interleukin-18 N0000171279 Receptors, Interleukin-2 N0000175271 Receptors, Interleukin-21 N0000168837 Receptors, Interleukin-3 ... Keratin-13 N0000175132 Keratin-14 N0000175329 Keratin-15 N0000175125 Keratin-16 N0000175131 Keratin-17 N0000175130 Keratin-18 ... Interleukin-17 N0000170942 Interleukin-18 N0000175299 Interleukin-18 Receptor alpha Subunit N0000175298 Interleukin-18 Receptor ...
GROWTH SUBSTANCES INTERLEUKIN-18 GROWTH SUBSTANCES INTERLEUKIN-2 GROWTH SUBSTANCES INTERLEUKIN-3 GROWTH SUBSTANCES INTERLEUKIN- ... AND HORM 18-HYDROXYDESOXYCORTICOSTERONE HORMONES, HORMONE SUBSTITUTES, AND HORM ACTIVINS HORMONES, HORMONE SUBSTITUTES, AND ... HORMONES 18-HYDROXYDESOXYCORTICOSTERONE HORMONES ACTIVINS HORMONES ADRENAL CORTEX HORMONES HORMONES ALDOSTERONE HORMONES ALPHA- ... IMMUNOLOGIC FACTORS INTERLEUKIN-18 IMMUNOLOGIC FACTORS INTERLEUKIN-2 IMMUNOLOGIC FACTORS INTERLEUKIN-3 IMMUNOLOGIC FACTORS ...
B1.650.940.800.575.100.18 Agave B1.650.940.800.575.100.18.249 B1.650.940.800.575.100.99.60.32 Agglutination G2.111.87.26 G2.111 ... 18-Hydroxydesoxycorticosterone D4.808.745.745.654.339.400 D4.210.500.745.745.654.339.400 19-Iodocholesterol D4.808.247.222. ... 18-Hydroxycorticosterone D4.808.745.745.654.237.400 D4.210.500.745.745.654.237.400 ...

No FAQ available that match "18 hydroxydesoxycorticosterone"